Table 1. IC₅₀ values (μM) of Ru1 and Ru2 against the selected human cancer cell lines and normal cell lines (HBE)^#.

Complexes	IC50 (μM)
	A549	NCl-H460	HepG2	MCF-7	HeLa	HBE
Ru1	21.24 ± 1.24	23.10 ± 3.2	26.15 ± 1.52a	46.17 ± 3.27b	40.17 ± 3.27b	176.47 ± 13.41b
Ru2	46.52 ± 3.84d	51.23 ±3.81d	42.54 ± 3.45d	63.41 ± 4.56c	62.70 ± 3.74d	191.54 ± 10.24
Cisplatin	26.71 ± 1.47c	29.92 ± 2.97	28.22 ± 2.19	34.14 ± 2.36b	20.47 ± 2.08b	22.53 ± 2.47b

^#Drug-treatment period was 24 h. Different cells were treated with tested compounds vs. A549 cells,

^ap < 0.05,

^bp < 0.001; homologous cells were treated with various complexes vs. Ru1-treated cells,

^cp < 0.05,

^dp < 0.001.

Each data represents the mean ± SD of at least three independent experiments.